Lifesci Capital Upgrades Inhibikase Therapeutics (NASDAQ:IKT) to Strong-Buy

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by research analysts at Lifesci Capital to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Several other equities research analysts have also commented on IKT. Wall Street Zen upgraded Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. HC Wainwright raised Inhibikase Therapeutics to a “strong-buy” rating in a research note on Friday, December 26th. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Finally, Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Three research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy”.

Inhibikase Therapeutics Price Performance

Shares of NASDAQ IKT opened at $2.05 on Monday. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.58. The company has a market capitalization of $154.11 million, a price-to-earnings ratio of -5.26 and a beta of 0.84. The firm’s 50 day simple moving average is $1.73.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.